SLC22A3 and cervical carcinoma: Studies involving resistant cell lines derived from cervical cancer and oral squamous cell carcinoma slowed downregulation of OCT3, corroborating our results that this transporter is a major contributor for the generation of resistance after platinum drug treatment [37, 38].